研究等業績 - その他 - 成田 伸太郎
-
PREDICTIVE RISK FACTORS OF POST-TRANSPLANT HIGH-GRADE CMV REACTIVATION IN CMV-SEROPOSITIVE PATIENTS IN THE MODERN IMMUNOSUPPRESSIVE ERA
Mitsuru Saito, Shigeru Satoh, Hiroshi Tsuruta, Susumu Akihama, Takamitsu Inoue, Shintaro Narita, Norihiko Tsuchiya, Tomonori Habuchi
JOURNAL OF UROLOGY ( ELSEVIER SCIENCE INC ) 193 ( 4 ) E1068 - E1068 2015年04月
研究発表要旨（国際会議）
-
PROGNOSTIC FACTORS FOR OVERALL SURVIVAL IN PATIENTS WITH CASTRATION-RESISTANT PROSTATE CANCER TREATED BY INTERMITTENT CHEMOTHERAPY WITH DOCETAXEL AND PREDNISOLONE
Shintaro Narita, Takuya Koie, Shigeyuki Yamada, Kazuhiko Orikasa, Shigeki Matsuo, Hiroshi Aoki, Shigeto Ishidoya, Senji Hoshi, Norihiko Tsuchiya, Chikara Ohyama, Yoichi Arai, Tomonori Habuchi
JOURNAL OF UROLOGY ( ELSEVIER SCIENCE INC ) 193 ( 4 ) E1086 - E1087 2015年04月
研究発表要旨（国際会議）
-
血清3分岐、4分岐N型糖鎖は去勢抵抗性前立腺癌予測マーカーとなりえる
米山 徹, 石橋 祐介, 飛澤 悠葵, 畠山 真吾, 成田 伸太郎, 古家 琢也, 羽渕 友則, 大山 力
日本泌尿器科学会総会 ( (一社)日本泌尿器科学会総会事務局 ) 103回 493 - 493 2015年04月
-
高脂肪食摂取によるマウス前立腺癌xenograftの腫瘍増大とリン脂質代謝の変化
小泉 淳, 黄 明国, 中西 広樹, 秋濱 晋, 沼倉 一幸, 鶴田 大, 齋藤 満, 井上 高光, 成田 伸太郎, 土谷 順彦, 佐藤 滋, 佐々木 雄彦, 羽渕 友則
日本泌尿器科学会総会 ( (一社)日本泌尿器科学会総会事務局 ) 103回 594 - 594 2015年04月
-
マウス去勢抵抗性前立腺癌骨転移モデルにおける去勢による骨密度低下と骨転移促進効果
高山 孝一朗, 井上 高光, 成田 伸太郎, 黄 明国, 鶴田 大, 秋濱 晋, 齋藤 満, 土谷 順彦, 羽渕 友則
日本泌尿器科学会総会 ( (一社)日本泌尿器科学会総会事務局 ) 103回 527 - 527 2015年04月
-
分子標的薬時代における1st-Lineインターフェロン単独療法適応の検討
井上 高光, 土谷 順彦, 鶴田 大, 秋濱 晋, 齋藤 満, 成田 伸太郎, 羽渕 友則
日本泌尿器科学会総会 ( (一社)日本泌尿器科学会総会事務局 ) 103回 775 - 775 2015年04月
-
局所進行腎盂尿管癌に対する補助化学療法の意義 腎機能低下症例における薬剤選択
成田 伸太郎, 羽渕 友則
日本泌尿器科学会総会 ( (一社)日本泌尿器科学会総会事務局 ) 103回 389 - 389 2015年04月
-
腎癌と肥満およびアディポネクチンシグナルの関連検討
成田 伸太郎, 伊藤 隆一, 鶴田 大, 秋濱 晋, 齋藤 満, 井上 高光, 土谷 順彦, 佐藤 滋, 羽渕 友則
日本泌尿器科学会総会 ( (一社)日本泌尿器科学会総会事務局 ) 103回 643 - 643 2015年04月
-
腎細胞癌進展とインスリンレセプター発現との逆関連 臨床およびマウス実験での検討
高橋 誠, 井上 高光, 黄 明国, 鶴田 大, 秋濱 晋, 齋藤 満, 成田 伸太郎, 土谷 順彦, 佐藤 滋, 羽渕 友則
日本泌尿器科学会総会 ( (一社)日本泌尿器科学会総会事務局 ) 103回 594 - 594 2015年04月
-
進行性腎癌におけるアキシチニブの効果予測を目的とした血清バイオマーカーの探索
鈴木 直子, 土谷 順彦, 成田 伸太郎, 井上 高光, 齋藤 満, 秋濱 晋, 鶴田 大, 佐藤 滋, 羽渕 友則
日本泌尿器科学会総会 ( (一社)日本泌尿器科学会総会事務局 ) 103回 770 - 770 2015年04月
-
A phase III, multicenter, randomized, controlled study of maximum androgen blockade with versus without zoledronic acid in treatment-naive prostate cancer patients with bone metastases: Results of ZAPCA study.
Tomomi Kamba, Toshiyuki Kamoto, Yousuke Shimizu, Shunichi Namiki, Kiyohide Fujimoto, Hiroaki Kawanishi, Fuminori Sato, Shintaro Narita, Takefumi Satoh, Hideo Saito, Mikio Sugimoto, Jun Teishima, Naoya Masumori, Shin Egawa, Hideki Sakai, Yusaku Okada, Toshiro Terachi, Osamu Ogawa
JOURNAL OF CLINICAL ONCOLOGY ( AMER SOC CLINICAL ONCOLOGY ) 33 ( 7 ) 2015年03月
-
Association of pharmacokinetics of axitinib with treatment outcome and adverse events in advanced renal cell carcinoma patients.
Norihiko Tsuchiya, Ryoma Igarashi, Naoko Suzuki-Honma, Nobuhiro Fujiyama, Shintaro Narita, Takamitsu Inoue, Mitsuru Saito, Susumu Akihama, Hiroshi Tsuruta, Masatomo Miura, Tomonori Habuchi
JOURNAL OF CLINICAL ONCOLOGY ( AMER SOC CLINICAL ONCOLOGY ) 33 ( 7 ) 2015年03月
研究発表要旨（国際会議）
-
Treatment outcome of patients with intermediate- and poor-prognosis metastatic testicular cancer in the 2000s: A multicenter experience in Japan
Takahiro Kojima, Koji Kawai, Kunihiko Tsuchiya, Takashige Abe, Nobuo Shinohara, Toshiaki Tanaka, Naoya Masumori, Shigeyuki Yamada, Yoichi Arai, Shintaro Narita, Norihiko Tsuchiya, Tomonori Habuchi, Hiroyuki Nishiyama
JOURNAL OF CLINICAL ONCOLOGY ( AMER SOC CLINICAL ONCOLOGY ) 33 ( 7 ) 2015年03月
研究発表要旨（国際会議）
-
Prostate-specific antigen density predicts extracapsular extension and increased risk of biochemical recurrence in patients with high-risk prostate cancer who underwent radical prostatectomy.
Takuya Koie, Koji Mitsuzuka, Takahiro Yoneyama, Shintaro Narita, Sadafumi Kawamura, Yasuhiro Kaiho, Norihiko Tsuchiya, Tatsuo Tochigi, Tomonori Habuchi, Yoichi Arai, Chikara Ohyama, Tohru Yoneyama, Yuki Tobisawa
International journal of clinical oncology 20 ( 1 ) 176 - 81 2015年02月
BACKGROUND: Patients with advanced local-stage, high-grade prostate cancer (Pca) and high pretreatment prostate-specific antigen (PSA) levels have inferior outcomes compared to their counterparts with more favorable clinical characteristics. However, some patients exhibit favorable pathological features or experience long-term PSA-free survival after radical prostatectomy (RP). We retrospectively examined the ability of preoperative characteristics to predict pathological and oncological outcomes in high-risk Pca patients who underwent RP. METHODS: We examined data of 1,268 consecutive Pca patients treated with RP alone at 4 hospitals from the Michinoku Urological Cancer Study Group database. Preoperative predictors included age, PSA level, biopsy Gleason score, clinical T stage, and PSA density (PSAD). The outcome measures pathological T stage and PSA-free survival were evaluated by multivariate analysis. RESULTS: We identified 380 high-risk Pca patients, of which 44 % patients had extracapsular extension. Logistic regression analysis indicated that PSAD was an independent predictor of adverse pathologic stage. The 5-year PSA-free survival rates were 82.9 % for patients with PSAD ≤0.468 ng mL(-1) cm(-2) and 50.7 % for those with PSAD >0.468 ng mL(-1) cm(-2) (P < 0.0001). Multivariate analyses revealed that PSAD, cT, and the number of preoperative high-risk Pca criteria were independent predictors of PSA-free survival. CONCLUSIONS: PSAD may be an independent predictor of advanced pathological features and biochemical recurrence in high-risk Pca patients treated with RP alone. PSAD may be used for further risk stratification of high-risk Pca patients.
-
Effects of functional genetic polymorphisms in the CYP19A1 gene on prostate cancer risk and survival.
Sohei Kanda, Norihiko Tsuchiya, Shintaro Narita, Takamitsu Inoue, Mingguo Huang, Syuji Chiba, Susumu Akihama, Mitsuru Saito, Kazuyuki Numakura, Hiroshi Tsuruta, Shigeru Satoh, Seiichi Saito, Chikara Ohyama, Yoichi Arai, Osamu Ogawa, Tomonori Habuchi
International journal of cancer 136 ( 1 ) 74 - 82 2015年01月
CYP19 catalyzes the conversion of androgens to estrogens and is a critical enzyme affecting the sex hormone milieu. In this study, we investigated the functions of CYP19A1 polymorphisms and their associations with prostate cancer risk and clinical outcome. This case-control study evaluated the effects of three single nucleotide polymorphisms (SNPs) in CYP19A1 on the risk of prostate cancer in 330 prostate cancer patients and 354 normal controls. The associations between each SNP and sex hormone levels were evaluated in 164 healthy male patients. The functions of the SNPs were determined by reporter gene assays in PC3 and DU145 cell lines. Prostate-specific antigen nadir was evaluated in 142 patients with metastatic prostate cancer treated with androgen deprivation therapy. Cancer-specific survival (CSS) was determined in 166 patients with metastatic prostate cancer, to evaluate the influence of the three SNPs. Each variant allele of the three SNPs significantly decreased the risk of prostate cancer. Haplotype analysis showed that the T-A-G haplotype (corresponding to rs2470152-rs10459592-rs4775936) increased the risk of prostate cancer, while the C-C-A haplotype decreased the risk. The estrone/androstenedione ratio was significantly higher in men with the C allele of rs2470152, the C allele of rs10459592, and the A allele of rs4775936 in a gene-dosage-dependent manner. Patients with the variant allele at rs4775936 had significantly shorter CSS. These results indicate that CYP19A1 polymorphisms may influence prostate cancer risk and survival by modifying promoter activity, with subsequent effects on the sex hormone milieu.
-
Efficiency of pretreatment risk stratification systems for prostate cancer in a Japanese population treated with radical prostatectomy.
Takuya Koie, Koji Mitsuzuka, Shintaro Narita, Takahiro Yoneyama, Sadafumi Kawamura, Norihiko Tsuchiya, Tatsuo Tochigi, Tomonori Habuchi, Yoichi Arai, Chikara Ohyama
International journal of urology : official journal of the Japanese Urological Association 22 ( 1 ) 70 - 3 2015年01月
OBJECTIVE: To determine whether the currently available pretreatment risk classification systems are applicable in Japanese prostate cancer patients. METHODS: Using data obtained from 1264 consecutive patients with prostate cancer treated with radical prostatectomy at four hospitals in Japan, biochemical recurrence-free survival rates were estimated and compared between the D'Amico, the National Institute for Health and Clinical Excellence, the Cancer of the Prostate Strategic Urological Research Endeavor, the National Comprehensive Cancer Network, and the European Society of Medical Oncology risk groups by using the Kaplan-Meier method and log-rank test. RESULTS: The 5-year biochemical recurrence-free survival rates in the D'Amico low-, intermediate-, and high-risk groups were 88.3%, 84.7% and 66.9%, respectively (low and intermediate risk vs high risk, P < 0.001). The 5-year biochemical recurrence-free survival rates in the National Institute for Health and Clinical Excellence, National Comprehensive Cancer Network, and European Society of Medical Oncology low-, intermediate- and high-risk groups were 88.3%, 84.3%, and 60.3%, respectively (low and intermediate risk vs high risk, P < 0.001). The 5-year biochemical recurrence-free survival rates in the Cancer of the Prostate Strategic Urological Research Endeavor low-, intermediate-, and high-risk groups were 90%, 83.5% and 60.3%, respectively (low and intermediate risk vs high risk, P < 0.001). Low- and intermediate-risk groups according to any of the risk stratification systems did not show significant differences in biochemical recurrence-free survival. CONCLUSION: Current risk stratification systems do not discriminate between low- and intermediate-risk groups in the Japanese population. A novel, pretreatment risk stratification system including other prognostic factors is necessary for an adequate prostate cancer risk assessment in the Japanese population.
-
Characterization of clinical and genetic risk factors associated with dyslipidemia after kidney transplantation.
Kazuyuki Numakura, Hideaki Kagaya, Ryohei Yamamoto, Naoki Komine, Mitsuru Saito, Tsuruta Hiroshi, Susumu Akihama, Takamitsu Inoue, Shintaro Narita, Norihiko Tsuchiya, Tomonori Habuchi, Takenori Niioka, Masatomo Miura, Shigeru Satoh
Disease markers 2015 179434 - 179434 2015年
We determined the prevalence of dyslipidemia in a Japanese cohort of renal allograft recipients and investigated clinical and genetic characteristics associated with having the disease. In total, 126 patients that received renal allograft transplants between February 2002 and August 2011 were studied, of which 44 recipients (34.9%) were diagnosed with dyslipidemia at 1 year after transplantation. Three clinical factors were associated with a risk of having dyslipidemia: a higher prevalence of disease observed among female than male patients (P = 0.021) and treatment with high mycophenolate mofetil (P = 0.012) and prednisolone (P = 0.023) doses per body weight at 28 days after transplantation. The genetic association between dyslipidemia and 60 previously described genetic polymorphisms in 38 putative disease-associated genes was analyzed. The frequency of dyslipidemia was significantly higher in patients with the glucocorticoid receptor (NR3C1) Bcl1 G allele than in those with the CC genotype (P = 0.001). A multivariate analysis revealed that the NR3C1 Bcl1 G allele was a significant risk factor for the prevalence of dyslipidemia (odds ratio = 4.6; 95% confidence interval = 1.8-12.2). These findings may aid in predicting a patient's risk of developing dyslipidemia.
-
Clinical benefits of tubeless umbilical cutaneous ureterostomy.
Kazuyuki Numakura, Norihiko Tsuchiya, Makoto Takahashi, Hiroshi Tsuruta, Susumu Akihama, Mitsuru Saito, Takamitsu Inoue, Shintaro Narita, Mingguo Huang, Shigeru Satoh, Tomonori Habuchi
Canadian Urological Association journal = Journal de l'Association des urologues du Canada 9 ( 5-6 ) E379-83 2015年
INTRODUCTION: We assess a novel technique of tubeless bilateral cutaneous ureterostomy, with a single umbilical stoma, for bladder cancer patients with short ureters after cystectomy. The benefit of cutaneous ureterostomy is equal to other incontinent urinary diversions, when the tubeless procedure is successfully achieved. This simple technique makes it easy to monitor the upper urinary tract (UUT) and is beneficial to patients with a high risk of UUT recurrence. METHODS: This old and new surgical technique was used to perform total cystectomy and urinary diversion on three patients with bladder cancer at a high risk of UUT recurrence. RESULTS: Two men and one woman (mean age: 73 years) underwent this surgery and the mean follow-up period was 8.3 years. The surgical approaches were laparotomy (n = 2) and laparoscopy (n = 1). One case developed para-stomal erosion, whereas another developed ureteral stenosis requiring catheter reinsertion. Although postoperative hydronephrosis was observed in all cases, the mean preoperative and postoperative serum creatinine levels were 0.70 and 0.76, respectively. UUT recurrence was not observed during the follow-up period. CONCLUSION: This tubeless umbilical cutaneous ureterostomy procedure greatly improves the outcome of urinary diversion for cancer patients with short ureters at a high risk of UUT recurrence. The benefits are equivalent to other urinary diversions when the tubeless procedure is successfully achieved.
-
齋藤 満, 鶴田 大, 井上 高光, 成田 伸太郎, 土谷 順彦, 羽渕 友則
Japanese Journal of Endourology ( Japanese Society of Endourology ) 28 ( 1 ) 68 - 72 2015年
泌尿器科領域ではロボット支援腹腔鏡下前立腺摘除術（robot-assisted laparoscopic prostatectomy：RALP）の経験をもとに，他疾患に対してもロボット支援手術が導入されつつある．当科ではこれまでに進行性膀胱癌患者に対しロボット支援膀胱全摘除術（robot-assisted radical cystectomy：RARC）を8例に施行している． <br> RARC施行時は体位ならびに機器の配置はRALPに準じ，カメラポートはRALPよりも3-4cm頭側に配置し，さらに第2助手用5mmトロカールを1本追加，計7本のトロカールを留置した．全例で下腸間膜動脈分岐部までの拡大リンパ節郭清（extended pelvic lymph node dissection：ePLND）を施行した．尿路変更は回腸導管4例（完全腹腔内と腹腔外が2例ずつ），回腸利用自然排尿型代用膀胱2例（完全腹腔内と腹腔外が1例ずつ），尿管皮膚瘻が2例であった．手術時間の中央値は511（462-763）分，出血量の中央値は418（少量‐709）mLであった．平均郭清リンパ節数は30（18-35）個であった．本術式は安全に施行でき，輸血症例ならびに術後の重篤な合併症の発生は無かった．本稿では主にRARCにおけるePLNDの意義について論述する．
-
[Treatment for high-risk localized prostate cancer].
Shintaro Narita, Norihiko Tsuchiya, Tomonori Habuchi
Nihon rinsho. Japanese journal of clinical medicine 72 ( 12 ) 2212 - 6 2014年12月
High-risk localized prostate cancer encompasses a significant heterogeneity and the treatment strategy for this group of prostate cancer patients remains controversial. The definition of high-risk localized prostate cancer is not consistent in that which clinicopathological parameters are included as risk factors. Therefore, we need to be careful in comparing the treatment outcome of each report. Recently, there have been significant improvements in the radiotherapeutic and surgical management. High radiation dose levels, long-term androgen deprivation therapy, and the combination of brachytherapy may contribute to the improvement of radiation-based treatment. Although some patients can be cured by standard surgical approach, extended lymph node dissection and multimodal treatment with radiation and chemohormonal therapy may improve surgical outcome. This review focuses on the recent treatment strategy for high-risk localized prostate cancer.